The proposed legislation establishes a two-year moratorium on the administration of human gene therapy products to children under the age of eighteen and pregnant women in Idaho. This moratorium is intended to protect the health and safety of these vulnerable populations, particularly in light of concerns regarding the potential adverse effects of experimental gene therapies and immunizations. The bill defines "human gene therapy products" broadly, encompassing various genetic materials and modified organisms, and explicitly prohibits their use for infectious disease indications in the specified groups. However, the moratorium does not apply to gene therapy products used for cancer treatment or genetic disorders.

Additionally, the bill allows for exemptions to the moratorium if the legislature determines that a specific gene therapy product is safe based on available safety data, if informed consent procedures are in place, and if compensation for adverse outcomes is assured. It also permits exemptions for products involved in clinical trials or those provided under expanded access for serious conditions. The legislation is framed as the "Maintaining Idaho Children's Health Act" and is set to take effect immediately upon passage and approval, reflecting the urgency of the matter as declared by the legislature.